Rachel A. Burga
YOU?
Author Swipe
View article: 348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA
348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA Open
Background We have previously demonstrated the successful generation of membrane-bound IL15 (mbIL15) engineered TIL (cytoTIL15™ therapy) from solid tumors, and acetazolamide (ACZ)-driven regulated expression of mbIL15 resulted in TIL persi…
View article: Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 1. In vitro cytotoxicity assay
View article: Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 1. In vitro cytotoxicity assay
View article: Supplementary Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Supplementary Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma Open
Supplementary Table 1: NK cell persistence. Fig. S1. Characterizing SHSY5Y neuroblastoma. Fig. S2. NK cell functionality against HTLA230 neuroblastoma. Fig. S3. Verification of NK Cell Sorting. Fig. S4. NK Cell Phenotype and Proliferation.…
View article: Supplementary Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Supplementary Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma Open
Supplementary Table 1: NK cell persistence. Fig. S1. Characterizing SHSY5Y neuroblastoma. Fig. S2. NK cell functionality against HTLA230 neuroblastoma. Fig. S3. Verification of NK Cell Sorting. Fig. S4. NK Cell Phenotype and Proliferation.…
View article: Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 3. Radiographic studies
View article: Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma Open
Purpose:The ability of natural killer (NK) cells to lyse allogeneic targets, without the need for explicit matching or priming, makes them an attractive platform for cell-based immunotherapy. Umbilical cord blood is a practical source for …
View article: Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 4. Cytokine response to treatment
View article: Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 2. Flow cytometry gating
View article: Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Purpose: Chimeric antigen receptor–modified T cells (CAR-T) have demonstrated encouraging results in early-phase clinical trials. Successful adaptation of CAR-T technology for CEA-expressing adenocarcinoma liver metastases, a major cause o…
View article: Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 2. Flow cytometry gating
View article: Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Purpose: Chimeric antigen receptor–modified T cells (CAR-T) have demonstrated encouraging results in early-phase clinical trials. Successful adaptation of CAR-T technology for CEA-expressing adenocarcinoma liver metastases, a major cause o…
View article: Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 3. Radiographic studies
View article: Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma Open
Purpose:The ability of natural killer (NK) cells to lyse allogeneic targets, without the need for explicit matching or priming, makes them an attractive platform for cell-based immunotherapy. Umbilical cord blood is a practical source for …
View article: Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases Open
Supplemental Figure 4. Cytokine response to treatment
View article: 390 Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15® therapy) in an allogeneic melanoma PDX model
390 Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15® therapy) in an allogeneic melanoma PDX model Open
Background CytoTIL15® therapy is an IL2-independent, engineered TIL product which allows pharmacological control of membrane-bound IL15 (mbIL15). We have previously shown that cytoTIL15® TILs demonstrate enhanced persistence and anti-tumor…
View article: 369 Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments
369 Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments Open
Background The clinical impact of tumor infiltrating lymphocytes (TIL) cell products is currently limited by suboptimal persistence and potency, as well as the need for high-dose adjuvant IL-2 treatment, which is associated with severe tox…
View article: Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer
Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer Open
Significance Brain metastases are among the most severe complications of systemic breast cancer, and overexpression of the human epidermal growth factor receptor 2 (HER2) in breast cancer cells increases the incidence of brain metastases i…
View article: 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo
166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo Open
Background Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated tremendous promise in clinical trials for patients with solid or metastatic tumors.1 However, current TIL therapy requires systemic administration…
View article: An Engineered Prussian Blue Nanoparticles‐Based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH‐MYCN Neuroblastoma Model
An Engineered Prussian Blue Nanoparticles‐Based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH‐MYCN Neuroblastoma Model Open
A combination therapy using Prussian blue nanoparticles (PBNP) as photothermal therapy (PTT) agents coated with CpG oligodeoxynucleotides, an immunologic adjuvant, as a nanoimmunotherapy (CpG‐PBNP‐PTT) for neuroblastoma (NB) is described. …
View article: Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma
Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma Open
Glioma-associated myeloid cells generate polyamines to survive and function within the acidic tumor microenvironment.
View article: EXTH-43. GENERATION OF A B-CELL-BASED VACCINE FOR THE TREATMENT OF GLIOBLASTOMA
EXTH-43. GENERATION OF A B-CELL-BASED VACCINE FOR THE TREATMENT OF GLIOBLASTOMA Open
Immunotherapy has revolutionized the treatment of many tumors. However, most glioblastoma (GBM) patients have not, so far, benefited from such successes. With the goal of exploring ways to boost anti-GBM immunity, we developed a B-cell-bas…
View article: 167 B-cell-based vaccination elicit potent immunity against glioblastoma
167 B-cell-based vaccination elicit potent immunity against glioblastoma Open
Background Despite the tremendous effort in basic, translational and clinical research, the standard-of-care of patients with glioblastoma (GBM) has been virtually unchanged for the past two decades, aside from tumor-treating fields. GBM i…
View article: Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma
Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma Open
Immunotherapy has revolutionized the treatment of many tumors. However, most glioblastoma (GBM) patients have not, so far, benefited from such successes. With the goal of exploring ways to boost anti-GBM immunity, we developed a B cell–bas…
View article: PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function
PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function Open
Natural killer (NK) cells are attractive effector cells of the innate immune system against human immunodeficiency virus (HIV) and cancer. However, NK cell therapies are limited by the fact that target cells evade NK cells, for example, in…
View article: Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma Open
Purpose: The ability of natural killer (NK) cells to lyse allogeneic targets, without the need for explicit matching or priming, makes them an attractive platform for cell-based immunotherapy. Umbilical cord blood is a practical source for…